| |||||||||||||||||||||||
| |||||||||||||||||||||||
Media HD AmeriTV Internet television service HD AmeriTV of New York and Hong Kong has raised approximately $45 million in funding. The proceeds will be used for product development, global expansion, localization, and service offerings. European investment banking firm First Mutual Credit led the round with G Trade Securities of New York and three other undisclosed investors participating. Founded in January 2004, the company operates an Internet platform that enables interactive, advertising-supported television programming. --G.W. Fusion Media Group Wenham, Mass.-based media company Fusion Media Group has closed a $7.5 million Series A funding that will allow it to acquire the assets of Genesis Media Advertising of Tyler, Texas. The capital for the purchase came from Waltham, Mass.-based Key Venture Partners. FMG is an outdoor advertising company that buys majority interests in independent operators, providing partial liquidity to the Principals or other shareholders, while keeping their local managers in place to continue running the business. --G.W. Semiconductors DisplayLink DisplayLink Corp. of Palo Alto, Calif., has received $24 million in a Series C round led by new investor DAG Ventures of Palo Alto, Calif. Also participating were existing investors Atlas Venture of Boston, and Europe's Balderton Capital and DFJ Esprit. The funds will be used for product development. To date, the company has raised a total of $51 million in venture capital. DisplayLink develops semiconductor and software technology for network display applications that enable seamless and high-quality connections between computers and displays using standard wired or wireless networking protocols. --G.W. Software Carnegie Speech Software developer Carnegie Speech of Pittsburgh has received a $6 million investment from Osage Ventures of Bala Cynwyd, Pa. The capital will be used to expand sales and marketing, and to open international offices starting with India. Carnegie Speech develops and sells software for accessing and teaching spoken language skills. Its technology uses speech recognition to identify errors in sound, grammar and rhythm of the language. --G.W. Internet - Retail Allurent Online shopping technology provider Allurent Inc. of Cambridge, Mass., has secured an undisclosed amount of second round financing led by Polaris Venture Partners of Waltham, Mass. Also participating is GSI Commerce Inc. Allurent's software is designed for Internet retailers to use to enhance online shopping experiences from initial browsing through final purchase. The capital will be used to grow the staff, and for direct sales and professional services teams. --G.W. Biotech CellFor Vancouver, B.C.-based CellFor Inc., an agricultural biotechnology developer for the timber industry, raised $24.5 million in a Series D round to ramp up production capability to take the company to profitability within two years, and to pursue new possible markets in biofuels and carbon credit trading. The round included most of Vancouver, B.C.-based CellFor's prior investors including ATP Capital and CSFB Private Equity, both of New York and GrowthWorks Capital and BDC Venture Capital, both of Vancouver, and included a handful of unnamed late stage financial investors. Strategic investor E.I. duPont de Nemours and Co. of Wilmington, Del., did not participate in the current round, but invested additional money in the company earlier this year. The new round brings total investment in the eight-year-old startup to about $100 million, and will primarily go to expanding growing facilities to meet demand for genetically selected loblolly pine seedlings for timber cultivation. The company will deliver nearly 40 million seedlings to timber growers across the southeastern United States this year, with additional markets germinating in South America and New Zealand. --Clifford Carlsen Anaptys La Jolla, Calif.-based antibody discovery startup Anaptys Biosciences Inc. raised $33.9 million in a Series B round led by Novo A/S of Denmark to bring a small number of initial products into clinical trials, and to build a robust industrial platform for identifying additional novel antibodies for internal development and licensing. The deal drew additional support from Frazier Healthcare Ventures of Seattle, Palo Alto, Calif.-based Alloy Ventures Inc., WS Investment Co. of Palo Alto and Santa Barbara-based Numenor Ventures LLC as well as founding investor Avalon Partners of La Jolla, Calif. The new investment follows initial funding of $3 million to develop proof-of-concept of the company's drug discovery platform and to identify a small number of new antibodies, and is expected to allow the company to take two products into clinical testing, with a lead candidate advancing to Phase 2 trials. --Clifford Carlsen Arterial Remodeling Bioresorbable stent company Arterial Remodeling Technologies of Paris has closed on a €5.5 million ($7.8 million) venture financing. To date, ART has raised €10 million ($14.2 million) in funding. The round included French investors Matignon Technologies and SGAM Alternative Investments. The proceeds will be used to pursue CE Mark clearance for the company's first product, a bioresorbable stent that dismantles in vivo. --G.W. Akermin Biotech startup Akermin Inc. of St. Louis has raised $4.955 million in its Series A Phase 2 financing round, the first stage of which was completed in March and the second in September 2007. This round brings total funding since inception of the company to just under $8.5 million. Investors include Prolog Ventures of St. Louis, OnPoint Technologies of Maitland, Fla., Chrysalix Energy of Vancouver, Canada and the St. Louis Arch Angels. The company is developing enzymes to replace precious metals now used as catalysts in fuel cells, and to improve the performance of enzymes in food processing and fine chemical production. The capital will be used for application development. --G.W. Pharmaceuticals Piedmont Piedmont Pharmaceuticals LLC of Greensboro, N.C., has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other undisclosed investors. The specialty pharmaceutical company is focused on parasitology and drug delivery systems for human and companion animal use. The funding will advance Phase 3 clinical trials of the company's insecticide-free head lice treatment. --G.W. Informatics CaseNET Waltham, Mass.-based CaseNET Inc. has raised a $7.5 million Series B financing. The funding was led by new investor HLM Venture Partners of Boston, which contributed $4 million to the round, joined by existing investors Sigma Partners of Boston, Aurora Funds of Durham, N.C., and Howard Cox. Peter Grua, a partner at HLM, will join the CaseNET board of directors. The health care information company offers health care enterprises and government agencies a software platform for medical and care management. --G.W.  Deal Video
    Community
 Elsewhere on The Deal.comDealwatchThe Deal MagazineCorporate Dealmaker
The Deal VideoCategories
Blog roll
Archives
| |||||||||||||||||||||||
| |||||||||||||||||||||||
